This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charpentier, C.
Right arrow Articles by Hance, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charpentier, C.
Right arrow Articles by Hance, A. J.

 Previous Article  |  Next Article 

Journal of Virology, April 2004, p. 4234-4247, Vol. 78, No. 8
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.8.4234-4247.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors

Charlotte Charpentier, Dominic E. Dwyer,{dagger} Fabrizio Mammano, Denise Lecossier, François Clavel, and Allan J. Hance*

INSERM U552, Hôpital Bichat-Claude Bernard, 75018 Paris, France

Received 19 September 2003/ Accepted 22 December 2003

Human immunodeficiency virus type 1 (HIV-1) drug resistance results from the accumulation of mutations in the viral genes targeted by the drugs. These genetic changes, however, are commonly detected and monitored by techniques that only take into account the dominant population of plasma virus. Because HIV-1-infected patients harbor a complex and diverse mixture of virus populations, the mechanisms underlying the emergence and the evolution of resistance are not fully elucidated. Using techniques that allow the quantification of resistance mutations in minority virus species, we have monitored the evolution of resistance in plasma virus populations from patients failing protease inhibitor treatment. Minority populations with distinct resistance genotypes were detected in all patients throughout the evolution of resistance. The emergence of new dominant genotypes followed two possible mechanisms: (i) emergence of a new mutation in a currently dominant genotype and (ii) emergence of a new genotype derived from a minority virus species. In most cases, these population changes were associated with an increase in resistance at the expense of a reduction in replication capacity. Our findings provide a preliminary indication that minority viral species, which evolve independently of the majority virus population, can eventually become dominant populations, thereby serving as a reservoir of diversity and possibly accelerating the development of drug resistance.

* Corresponding author. Mailing address: INSERM U.552 Hôpital Bichat-Claude Bernard 46, Rue Henri Huchard, 75018 Paris, France. Phone: 33-1-40-25-63-55. Fax: 33-1-40-25-63-70. E-mail: hance{at}bichat.inserm.fr.

{dagger} Present address: Department of Virology, Westmead Hospital, University of Sydney, Wentworthville, Australia.

Journal of Virology, April 2004, p. 4234-4247, Vol. 78, No. 8
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.8.4234-4247.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hauser, A., Mugenyi, K., Kabasinguzi, R., Bluethgen, K., Kuecherer, C., Harms, G., Kunz, A. (2009). Detection and Quantification of Minor Human Immunodeficiency Virus Type 1 Variants Harboring K103N and Y181C Resistance Mutations in Subtype A and D Isolates by Allele-Specific Real-Time PCR. Antimicrob. Agents Chemother. 53: 2965-2973 [Abstract] [Full Text]  
  • Xu, Z., Fan, X., Xu, Y., Di Bisceglie, A. M. (2008). Comparative Analysis of Nearly Full-Length Hepatitis C Virus Quasispecies from Patients Experiencing Viral Breakthrough during Antiviral Therapy: Clustered Mutations in Three Functional Genes, E2, NS2, and NS5a. J. Virol. 82: 9417-9424 [Abstract] [Full Text]  
  • Poon, A. F. Y., Kosakovsky Pond, S. L., Richman, D. D., Frost, S. D. W. (2007). Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients. J. Virol. 81: 13598-13607 [Abstract] [Full Text]  
  • Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. J Antimicrob Chemother 60: 881-884 [Abstract] [Full Text]  
  • Nora, T., Charpentier, C., Tenaillon, O., Hoede, C., Clavel, F., Hance, A. J. (2007). Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral Treatment. J. Virol. 81: 7620-7628 [Abstract] [Full Text]  
  • Parisi, S. G., Boldrin, C., Cruciani, M., Nicolini, G., Cerbaro, I., Manfrin, V., Dal Bello, F., Franchin, E., Franzetti, M., Rossi, M. C., Cattelan, A. M., Romano, L., Zazzi, M., Andreoni, M., Palu, G. (2007). Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients. J. Clin. Microbiol. 45: 1783-1788 [Abstract] [Full Text]  
  • Charpentier, C., Nora, T., Tenaillon, O., Clavel, F., Hance, A. J. (2006). Extensive Recombination among Human Immunodeficiency Virus Type 1 Quasispecies Makes an Important Contribution to Viral Diversity in Individual Patients. J. Virol. 80: 2472-2482 [Abstract] [Full Text]  
  • Palmer, S., Kearney, M., Maldarelli, F., Halvas, E. K., Bixby, C. J., Bazmi, H., Rock, D., Falloon, J., Davey, R. T. Jr., Dewar, R. L., Metcalf, J. A., Hammer, S., Mellors, J. W., Coffin, J. M. (2005). Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis. J. Clin. Microbiol. 43: 406-413 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»